Radio(chemo)therapy in anaplastic thyroid cancer-high locoregional but low distant control rates-a monocentric analysis of a tertiary referral center.
Anaplastic thyroid cancer
Chemotherapy
Multimodal treatment
Radiation dose
Radiotherapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
16
04
2021
accepted:
03
04
2022
pubmed:
7
5
2022
medline:
22
10
2022
entrez:
6
5
2022
Statut:
ppublish
Résumé
Anaplastic thyroid cancer (ATC) is a lethal disease with highly aggressive disease progression. This study analyses the influence of radio(chemo)therapy, R(C)T, on disease control, survival rates and predictors for survival. A total of 33 patients with ATC, treated at a tertiary referral center between May 2001 and April 2020 were included. Univariate and multivariate analysis were used to investigate correlates of R(C)T and predictors on disease control and survival rates. Median follow-up was 4 months. In UICC stage IVA and IVB median overall survival (OS) was 8 months, median progression-free survival (PFS) was 6 months. Patients with UICC stage IVA and IVB and patients being irradiated with a radiation dose of more than 60 Gy showed increased OS. Of these patients, 3 were alive and free from disease. All of them receiving cisplatin-based radiochemotherapy and a minimum radiation dose of 66 Gy. UICC stage IVC showed a median OS of 2.5 months and a median PFS of 1 month. Only 2 of 16 patients had local failure. Depending on UICC stage, RT with high radiation dose can lead to improved OS or at least higher locoregional control. A limiting factor is the high incidence of distant metastases; therefore modern systemic treatment options should be integrated into multimodal therapy concepts.
Sections du résumé
BACKGROUND
Anaplastic thyroid cancer (ATC) is a lethal disease with highly aggressive disease progression. This study analyses the influence of radio(chemo)therapy, R(C)T, on disease control, survival rates and predictors for survival.
PATIENTS AND METHODS
A total of 33 patients with ATC, treated at a tertiary referral center between May 2001 and April 2020 were included. Univariate and multivariate analysis were used to investigate correlates of R(C)T and predictors on disease control and survival rates.
RESULTS
Median follow-up was 4 months. In UICC stage IVA and IVB median overall survival (OS) was 8 months, median progression-free survival (PFS) was 6 months. Patients with UICC stage IVA and IVB and patients being irradiated with a radiation dose of more than 60 Gy showed increased OS. Of these patients, 3 were alive and free from disease. All of them receiving cisplatin-based radiochemotherapy and a minimum radiation dose of 66 Gy. UICC stage IVC showed a median OS of 2.5 months and a median PFS of 1 month. Only 2 of 16 patients had local failure.
CONCLUSION
Depending on UICC stage, RT with high radiation dose can lead to improved OS or at least higher locoregional control. A limiting factor is the high incidence of distant metastases; therefore modern systemic treatment options should be integrated into multimodal therapy concepts.
Identifiants
pubmed: 35522270
doi: 10.1007/s00066-022-01943-0
pii: 10.1007/s00066-022-01943-0
pmc: PMC9581821
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
994-1001Informations de copyright
© 2022. The Author(s).
Références
Cancer. 2005 Apr 1;103(7):1330-5
pubmed: 15739211
Eur Arch Otorhinolaryngol. 2020 May;277(5):1507-1514
pubmed: 32060602
Cancer. 2020 Jan 15;126(2):444-452
pubmed: 31593317
Cancer Cytopathol. 2022 Mar;130(3):174-180
pubmed: 34618407
Strahlenther Onkol. 2020 Jun;196(6):542-551
pubmed: 32211941
J Clin Oncol. 2018 Jan 1;36(1):7-13
pubmed: 29072975
World J Surg. 2014 Sep;38(9):2311-6
pubmed: 24687351
Thyroid. 2018 Jun;28(6):739-747
pubmed: 29774792
Curr Treat Options Oncol. 2020 Aug 7;21(10):78
pubmed: 32767129
Head Neck. 2007 Aug;29(8):765-72
pubmed: 17274052
Radiat Oncol J. 2018 Jun;36(2):103-113
pubmed: 29983030
Eur J Cancer. 2016 May;59:34-45
pubmed: 27014798
Cancers (Basel). 2020 Sep 03;12(9):
pubmed: 32899355
Head Neck. 2020 Apr;42(4):678-687
pubmed: 31845469
World J Surg. 2012 Jun;36(6):1247-54
pubmed: 22311136
Gland Surg. 2020 Jan;9(Suppl 1):S28-S42
pubmed: 32055496
Eur J Endocrinol. 2016 Dec;175(6):521-529
pubmed: 27926471
Cancer. 2017 May 1;123(9):1653-1661
pubmed: 28026871
Thyroid. 2021 Jul;31(7):1076-1085
pubmed: 33509020
Head Neck. 2010 Jul;32(7):829-36
pubmed: 19885924
Strahlenther Onkol. 2019 Sep;195(9):805-818
pubmed: 31222468
Ann Surg Oncol. 2014 May;21(5):1665-70
pubmed: 24554064
Thyroid Res. 2020 Nov 24;13(1):17
pubmed: 33292371
Cancers (Basel). 2019 Aug 15;11(8):
pubmed: 31443283
Head Neck. 2016 Apr;38 Suppl 1:E2083-90
pubmed: 26894506
Strahlenther Onkol. 2020 Oct;196(10):868-878
pubmed: 32495038
Ann Oncol. 2019 Dec 1;30(12):1856-1883
pubmed: 31549998
Strahlenther Onkol. 2021 Mar;197(3):231-245
pubmed: 32588101
Am J Transl Res. 2019 Sep 15;11(9):5888-5896
pubmed: 31632557
Ann Surg Oncol. 2002 Jan-Feb;9(1):57-64
pubmed: 11833496
PLoS One. 2016 Oct 19;11(10):e0164840
pubmed: 27760217